VANCOUVER, May 26, 2020 /CNW/ – Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity”) (CSE: CGN; FWB: 1UB; OTCQB: CGNSF) today announced the…
Read More
Background: Cognitive impairment is common in patients with multiple sclerosis (MS). Accurate and repeatable measures of cognition have the potential…
VANCOUVER, April 1, 2020 /CNW/ – Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity”) (CSE: CGN; FWB: 1UB; OTCQB: CGNSF) is continuing to…
VANCOUVER, Feb. 18, 2020 /CNW/ – Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity”) (CSE: CGN; FWB: 1UB; OTCQB: CGNSF) has today reported…
VANCOUVER, Jan. 21, 2020 /CNW/ – Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity”) (CSE: CGN; FWB: 1UB; OTCQB: CGNSF) today announced that…
Cognetivity Neurosciences announces regulatory approval of first CE-marked medical device Vancouver, British Columbia, January 7, 2020 – Cognetivity Neurosciences…
Regulatory approval will establish the company’s first CE-marked product. CE marking allows sale of device for medical environments across Europe. VANCOUVER, Dec….
RAZOR reporters visit a company that has developed an AI detector to pick up early signs of dementia
“London-based firm Cognetivity Neurosciences has developed a simple five-minute iPad-based test that can spot the early signs of dementia. With…
VANCOUVER, Nov. 13, 2019 /CNW/ – Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity”) (CSE: CGN; FWB: 1UB; OTCQB: CGNSF) today announced the…
VANCOUVER, Oct. 29, 2019 /CNW/ – Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity”) (CSE: CGN; FWB: 1UB; OTCQB: CGNSF) today confirmed that…
